Related Experiment Video
Updated: Jan 19, 2026
Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia
Published on: February 17, 2023
Chinese patent medicine Bailing capsule for treating lupus nephritis: A protocol for systematic review and
Hui-Jie Ren1, Ya-Lei Sun, Bin Yuan
1Department of Pediatrics, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
Insights
This systematic review evaluates the Bailing capsule for treating lupus nephritis (LN). It compares its clinical efficacy and safety against routine treatments, offering evidence for patient care.
Area of Science:
- Nephrology
- Rheumatology
- Pharmacology
Background:
- Lupus nephritis (LN) poses significant challenges in systemic lupus erythematosus management.
- LN is a leading cause of morbidity and mortality in SLE patients.
- Bailing capsule, a Chinese patent medicine, is frequently used for LN, but its comparative efficacy is debated.
Purpose of the Study:
- To systematically review and meta-analyze the clinical efficacy and safety of Bailing capsule for lupus nephritis.
- To compare Bailing capsule's effectiveness with routine treatments for LN.
Main Methods:
- Comprehensive literature search across multiple databases (e.g., PubMed, EMBASE, CNKI) up to January 2019.
- Meta-analysis using Review Manager 5.3 software.
- Primary outcome: clinical effective rate. Secondary outcomes: SLEDAI, serum creatinine, 24-hour urine protein, C3 levels, and adverse effects.
Main Results:
- The meta-analysis will synthesize data to assess the clinical efficacy and safety of Bailing capsule in LN patients.
- Provides quantitative insights into treatment outcomes.
Conclusions:
- This study aims to generate robust evidence on the use of Bailing capsule for lupus nephritis.
- Findings will inform clinical practice guidelines and treatment strategies for LN.
Background:
Treatment of lupus nephritis (LN) remains challenging. LN remains the primary source of morbidity and mortality in patients with systemic lupus erythematosus. Chinese patent medicine Bailing capsule is commonly used for the treatment of LN. However, there is no consensus on the difference in clinical efficacy compared with routine treatment. Therefore, we plan to perform a systematic review and meta-analysis to review the clinical efficacy and safety of Bailing capsule for LN.
Methods:
Cochrane Central Register of Controlled Trials, PubMed, EMBASE, Chinese National Knowledge Infrastructure, Chinese Biomedical Database, Wanfang database, and VIP information database will be searched from their inception until January 2019. The meta-analysis will be conducted with Review Manager 5.3 software to systematically review the clinical efficacy and safety of Bailing capsule for LN. The primary outcome will include clinical effective rate, and the secondary outcomes will include Systemic Lupus Erythematosus Disease Activity Index, serum creatinine, 24-hour urine protein quantity, complement 3, and adverse effects.
Results:
This analysis will provide useful information about clinical efficacy and safety of Bailing capsule for LN.
Conclusions:
Our study will generate strong evidence of Bailing capsule for patients with LN and provide suggestions for clinical practice.
Related Concept Videos
04:34Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia
06:05Enema of Traditional Chinese Medicine for Patients with Severe Acute Pancreatitis
05:56A Traditional Chinese Medicine Characteristic Therapy for Bronchial Asthma: Moxibustion
06:24Establishment of Coloproctitis Cancer Model in Mice and Evaluation of Therapeutic Effect of Chinese Medicine
05:34Auricular Acupuncture as a Traditional Chinese Medicine Therapy for Chronic Obstructive Pulmonary Disease Combined with Sleep Disorders
05:26Press Needle: A Traditional Chinese Medicine Therapy for Myopia Patients with Dry Eye